Menu
Currency
GWAS Study

Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications.

Wolking S, Campbell C, Stapleton C et al.

34177598 PubMed ID
GWAS Study Type
936 Participants
59 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WS
Wolking S
CC
Campbell C
SC
Stapleton C
MM
McCormack M
DN
Delanty N
DC
Depondt C
JM
Johnson MR
KB
Koeleman BPC
KR
Krause R
KW
Kunz WS
MA
Marson AG
SJ
Sander JW
SG
Sills GJ
SP
Striano P
ZF
Zara F
SS
Sisodiya SM
CG
Cavalleri GL
LH
Lerche H
Chapter II

Abstract

Summary of the research findings

Objective: Resistance to anti-seizure medications (ASMs) presents a significant hurdle in the treatment of people with epilepsy. Genetic markers for resistance to individual ASMs could support clinicians to make better-informed choices for their patients. In this study, we aimed to elucidate whether the response to individual ASMs was associated with common genetic variation. Methods: A cohort of 3,649 individuals of European descent with epilepsy was deeply phenotyped and underwent single nucleotide polymorphism (SNP)-genotyping. We conducted genome-wide association analyses (GWASs) on responders to specific ASMs or groups of functionally related ASMs, using non-responders as controls. We performed a polygenic risk score (PRS) analyses based on risk variants for epilepsy and neuropsychiatric disorders and ASM resistance itself to delineate the polygenic burden of ASM-specific drug resistance. Results: We identified several potential regions of interest but did not detect genome-wide significant loci for ASM-specific response. We did not find polygenic risk for epilepsy, neuropsychiatric disorders, and drug-resistance associated with drug response to specific ASMs or mechanistically related groups of ASMs. Significance: This study could not ascertain the predictive value of common genetic variants for ASM responder status. The identified suggestive loci will need replication in future studies of a larger scale.

258 European ancestry cases, 678 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

936
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.